Ovary Removal Before Menopause Linked to Cognitive Impairment, Dementia Risk

Health & LifestyleNews
629

Listen to article (english)

Translate to Spanish or other 102 languages!

A new study shows that ovary removal before menopause is linked to decreased white matter in the brain later in life. Image for illustration purposes
A new study shows that ovary removal before menopause is linked to decreased white matter in the brain later in life. Image for illustration purposes

Medical News Today

- Advertisement -
  • A new study examined the brains of females who underwent full ovary removal before going through menopause.
  • Sometimes, females must undergo this type of procedure to treat conditions such as ovarian cancer or endometriosis.
  • The study’s findings show that females who undergo ovary removal before menopause have a decrease in white matter in their brains later in life. 
  • A decrease in white matter is linked to cognitive impairment.

A new study examined the cognitive effects of ovary removal in females.

Follow the link below to Medical News Today to read the full story:

https://www.medicalnewstoday.com/articles/ovary-removal-before-menopause-cognitive-decline-dementia-risk?slot_pos=article_2&utm_source=Sailthru%20Email&utm_medium=Email&utm_campaign=MNT%20Daily%20News&utm_content=2024-06-28&apid=&rvid=4ba4ec80177cae00eabc43b8bc6648d598c4a356d104663735777e0a0f8b5c9f

- Advertisement -

Information Source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Postpartum Urinary Incontinence Linked to Mental Health
Next article
Work-Related Nerve Injuries are Common with Repetitive Motions

More Articles

STHS Dedicating Latest “South Texas Healthy Living” Episode to Arthritis Education, July 26th

More than 58 million U.S. adults are living with doctor-diagnosed arthritis, according to the Centers for Disease Control and Prevention (CDC), making it the nation’s leading cause of disability.

No More Needles: FDA Approves First Daily Pill to Replace Injectable Cholesterol Drugs

The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). Image source: Merck.com.

Physicians Warn of Rising ER Visits Linked to E-Bikes and Scooters

Mega Doctor News CLEVELAND CLINIC - As electric bikes and scooters grow in...

STHS Heart Ranks Among Nation’s Top Hospitals for Heart Attack Care

Every year, more than 800,000 people in the United States suffer a heart attack, according to the Centers for Disease Control and Prevention, an event that occurs approximately every 40 seconds.
- Advertisement -